Sanofi to take control of Shantha Biotechnics
French pharmaceuticals group Sanofi-Aventis said Monday that it will take majority control of Indian vaccine manufacturer Shantha Biotechnics through the acquisition of a subsidiary of Merieux Alliance.
It is rumoured that multinational drugmaker Sanofi-Aventis is to acquire US-based biotechnology company Genzyme, a manufacturer of vaccines for genetic disorders and producer of drugs such as Cerezyme, a treatment for Gaucher's disease, and Fabrazyme, for Fabry disease.